Auro Laboratories Ltd

Auro Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Auro Laboratories Ltd

₹ 265 4.17%
05 Feb - close price
aurolabs.com BSE: 530233
About

Incorporated in 1989, Auro Laboratories Ltd is in the business of Bulk Drugs[1]

Key Points

Business Overview:[1]
ALL manufactures generic Active Pharmaceutical Ingredients (APIs), with a focus on anti-diabetics like Metformin HCL, a first-line treatment for type 2 diabetes. It also offers toll and custom manufacturing of APIs and intermediaries on a contract basis.

Website BSE
  • Market Cap ₹ 165 Cr.
  • Current Price ₹ 265
  • High / Low ₹ 303 / 159
  • Stock P/E 75.0
  • Book Value ₹ 69.9
  • Dividend Yield 0.00 %
  • ROCE %
  • ROE 4.28 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Stock is trading at 3.78 times its book value
  • Company has high debtors of 177 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2024 Jun 2025 Sep 2025
3.10 2.77 8.84
2.38 2.74 6.49
Operating Profit 0.72 0.03 2.35
OPM % 23.23% 1.08% 26.58%
0.31 0.42 0.98
Interest 0.28 0.28 0.96
Depreciation 0.27 0.27 0.65
Profit before tax 0.48 -0.10 1.72
Tax % 25.00% 0.00% 58.14%
0.36 -0.11 0.72
EPS in Rs 0.58 -0.18 1.16
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025
19.40
16.00
Operating Profit 3.40
OPM % 17.53%
0.66
Interest 1.08
Depreciation 1.10
Profit before tax 1.88
Tax % 2.13%
1.84
EPS in Rs 2.95
Dividend Payout % 0.00%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Stock Price CAGR
10 Years: 29%
5 Years: 21%
3 Years: 58%
1 Year: 15%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 4%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Sep 2025
Equity Capital 6.23 6.23
Reserves 36.74 37.35
42.72 43.94
13.41 23.25
Total Liabilities 99.10 110.77
21.05 76.84
CWIP 56.48 10.37
Investments 0.05 0.05
21.52 23.51
Total Assets 99.10 110.77

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025
Net Cash Flow

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025
Debtor Days 176.67
Inventory Days 145.45
Days Payable 246.11
Cash Conversion Cycle 76.01
Working Capital Days -14.30
ROCE %

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
52.09% 52.09% 52.09% 52.09% 52.15% 52.15% 52.15% 52.15% 52.17% 52.17% 52.17% 52.17%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
47.90% 47.90% 47.92% 47.90% 47.85% 47.84% 47.84% 47.84% 47.82% 47.82% 47.82% 47.80%
No. of Shareholders 10,90610,50110,2729,9059,4419,3359,2669,2659,1028,9168,8608,640

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings